t-cell

Documents about t-cell

• Novel Therapeutic Approach for Human T-cell Malignancies#802696ClinicalTrials.gov
• CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas#195329ClinicalTrials.gov
• Ageing combines CD4 T cell lymphopenia in secondary lymphoid organs and T cell accumulation in gut associated lymphoid tissue#231472HAL Science
• Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma#826383ClinicalTrials.gov
• CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma#143568ClinicalTrials.gov
• Romidepsin Maintenance After Allogeneic Stem Cell Transplantation#840793ClinicalTrials.gov
• Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma#833712ClinicalTrials.gov
• Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma#172309ClinicalTrials.gov
• Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation#291395Gestión del Repositorio Documental de la Universidad de Salamanca
• Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies#811486ClinicalTrials.gov
• Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia#238114ClinicalTrials.gov
• Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients#826280ClinicalTrials.gov
• The P2X7 Receptor as Regulator of T Cell Development and Function#430400IRIS
• CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma#846514ClinicalTrials.gov
• Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma#651232ClinicalTrials.gov
• T-Cell Project: Epidemiologic Component#835438ClinicalTrials.gov
• T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas#217037ClinicalTrials.gov
• Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)#832105ClinicalTrials.gov
• CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL#830724ClinicalTrials.gov
• Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma#831394ClinicalTrials.gov
• Copanlisib and Gemcitabine in Relapsed/Refractory PTCL#847317ClinicalTrials.gov
• Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype#839603ClinicalTrials.gov
• CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies#363603ClinicalTrials.gov
• Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control#189741Kyoto University Research Information Repository
• Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control#189780Kyoto University Research Information Repository
• CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma#810099ClinicalTrials.gov
• Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma#832638ClinicalTrials.gov
• Microfluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturing#610859bioRxiv / medRxiv
• Regulatory effects of smoking cessation on the cellular microenvironment and differentially expressed genes in precancerous lesions of pulmonary nodules in mice based on single-cell RNA sequencing and immune repertoire-sequencing#453126PLOS
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)#451413ClinicalTrials.gov
• Age-associated T cell immunity decreases circulating endothelial progenitor cells#408875IRIS
• Ipilimumab and Local Radiation for Selected Solid Tumors#121338ClinicalTrials.gov
• Targeting ZC3H12C improves T cell persistence and antitumor function in adoptive T cell therapy#243486bioRxiv / medRxiv
• Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma#839454ClinicalTrials.gov
• Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I#633726ClinicalTrials.gov
• A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007#840320ClinicalTrials.gov
• CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma#844069ClinicalTrials.gov
• Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy#307466ClinicalTrials.gov
• Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)#827994ClinicalTrials.gov
• CAR-T Cell Immunotherapy for HCC Targeting GPC3#123465ClinicalTrials.gov
• CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients#256882ClinicalTrials.gov
• Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation#292602Open Access LMU
• Comprehensive analysis of immune-related genes reveals diagnostic biomarkers and molecular subtypes in diabetic retinopathy#123679PLOS
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.#830779ClinicalTrials.gov
• A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma#834566ClinicalTrials.gov
• Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma#668832ClinicalTrials.gov
• CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation#801426ClinicalTrials.gov
• Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)#329515ClinicalTrials.gov
• Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma#346912ClinicalTrials.gov
• The Role of the T Cell Receptor Sequence in Shaping T Cell Functional Fate.#480881NCBI PubMed Central